| Literature DB >> 16421594 |
K Hiraoka1, M Miyamoto, Y Cho, M Suzuoki, T Oshikiri, Y Nakakubo, T Itoh, T Ohbuchi, S Kondo, H Katoh.
Abstract
The purpose of this study was to clarify the relationship between the number of tumour-infiltrating T lymphocytes and the clinicopathological features and clinical outcome in patients with non-small-cell lung cancer (NSCLC). Tissue specimens from 109 patients who underwent surgical resection for NSCLC were immunohistochemically analysed for CD4 and CD8 expression. Patients were classified into two groups according to whether their tumours exhibited a 'high' or 'low' level of CD8(+) or CD4(+) lymphocyte infiltration. Although the level of infiltration by CD8(+) T cells alone had no prognostic significance, the survival rate for patients with both 'high' CD8(+) and 'high' CD4(+) T-cell infiltration was significantly higher than that for the other groups (log-rank test, P=0.006). Multivariate analysis indicated that concomitant high CD8(+) and high CD4(+) T-cell infiltration was an independent favourable prognostic factor (P=0.0092). In conclusion, the presence of high levels of both CD8(+) T cells and CD4(+) T cells is a significant indicator of a better prognosis for patients with NSCLC, and cooperation between these cell populations may allow a significantly more potent antitumour response than either population alone.Entities:
Mesh:
Year: 2006 PMID: 16421594 PMCID: PMC2361103 DOI: 10.1038/sj.bjc.6602934
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Representative immunohistochemical staining of NSCLC tumour sections. (A) Adenocarcinoma (anti-CD8 antibody; original magnification, × 200). (B) Adenocarcinoma (anti-CD4 antibody, × 200). (C) Squamous cell carcinoma (anti-CD8 antibody, × 200). (D) Squamous cell carcinoma (anti-CD8 antibody, × 400). Arrows indicate CD8-positive stained lymphocytes.
Figure 2The correlation between the number of CD8+ T cells in cancer stroma and within cancer cell nests in patients with NSCLC.
Relationship between CD8+ T-cell infiltration and clinicopathological features in NSCLC
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
|
| ||||||
| <64 | 31 | 23 | 0.141 | 41 | 13 | 0.317 |
| ⩾64 | 25 | 30 | 37 | 18 | ||
|
| ||||||
| Male | 36 | 35 | 0.848 | 44 | 27 | 0.003 |
| Female | 20 | 18 | 34 | 4 | ||
|
| ||||||
| pT1 | 27 | 20 | 0.270 | 37 | 10 | 0.149 |
| pT2–4 | 29 | 33 | 41 | 21 | ||
|
| ||||||
| Negative | 34 | 43 | 0.019 | 56 | 21 | 0.675 |
| Positive | 22 | 10 | 22 | 10 | ||
|
| ||||||
| I | 29 | 38 | 0.033 | 51 | 16 | 0.183 |
| II–III | 27 | 15 | 27 | 15 | ||
|
| ||||||
| Poor | 4 | 9 | 0.113 | 6 | 7 | 0.047 |
| Other | 52 | 44 | 72 | 24 | ||
|
| ||||||
| Squamous cell carcinoma | 21 | 19 | 0.858 | 19 | 21 | <0.0001 |
| Other | 35 | 34 | 59 | 11 | ||
P-value was calculated by χ2 test or Fisher's exact test.
NSCLC=non-small-cell lung cancer.
Figure 3Kaplan–Meier analysis of overall survival according to (A) the level of infiltration by CD8+ T cells in cancer stroma, (B) the level of infiltration by CD4+ T cells in cancer stroma and (C) the simultaneous presence of high levels of infiltrating CD8+ T cells and CD4+ T cells in cancer stroma in patients with NSCLC. For details about the method of classification, see Materials and Methods. aHigh-CD8+/high-CD4+ group (n=26) vs others (n=83).
Univariate and multivariate analyses of T-cell infiltration status and clinicopathological features in 109 patients with NSCLC
|
|
| ||
|---|---|---|---|
|
|
| ||
| pT classification (2–4 | <0.0001 | 4.502 (2.17–9.34) | <0.0001 |
| Lymph node metastasis (positive | <0.0001 | 2.410 (1.33–4.35) | 0.0036 |
| Histological type (sqamous | 0.0001 | 1.726 (0.95–3.13) | 0.729 |
| CD8+/CD4+ T-cell infiltration (other | 0.006 | 3.221 (1.34–7.77) | 0.0092 |
NSCLC=non-small-cell lung cancer; CI=confidence interval.